NuCana (NASDAQ:NCNA) and Nuvalent (NASDAQ:NUVL) Head to Head Review

NuCana (NASDAQ:NCNA) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares NuCana and Nuvalent”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NuCana	N/A	N/A	-$34.37 million	($10.48)	-0.12
Nuvalent	N/A	N/A	-$126.22 million	($3.47)	-25.02

Nuvalent is trading at a lower price-to-earnings ratio than NuCana, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for NuCana and Nuvalent, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NuCana	0	1	1	0	2.50
Nuvalent	1	1	10	1	2.85

NuCana currently has a consensus target price of $25.00, suggesting a potential upside of 1,900.00%. Nuvalent has a consensus target price of $112.60, suggesting a potential upside of 29.69%. Given NuCana’s higher probable upside, research analysts plainly believe NuCana is more favorable than Nuvalent.

Volatility & Risk

NuCana has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.31, indicating that its share price is 31% more volatile than the S&P 500.

Insider and Institutional Ownership

44.0% of NuCana shares are owned by institutional investors. Comparatively, 97.3% of Nuvalent shares are owned by institutional investors. 31.2% of NuCana shares are owned by insiders. Comparatively, 12.5% of Nuvalent shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares NuCana and Nuvalent’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
NuCana	N/A	-314.47%	-112.60%
Nuvalent	N/A	-28.63%	-27.15%

Summary

Nuvalent beats NuCana on 8 of the 12 factors compared between the two stocks.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

About Nuvalent

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.